A Phase 1 Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics After Administration of SID1903 (Fixed-dose Combination) or Loose Combination in Healthy Adult Volunteers
Latest Information Update: 31 Oct 2022
At a glance
- Drugs Dapagliflozin/sitagliptin (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors SK Chemicals
- 24 Oct 2022 Status changed from recruiting to completed.
- 19 Jul 2022 New trial record